Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.

NCT05871541 is registered in ClinicalTrials.gov with Immorna Biotherapeutics, Inc. as lead sponsor.

NCT NCT05871541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05871541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.
Lead sponsor
Immorna Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 26, 2023
Completion date
March 25, 2024
Enrollment
75 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster (hz), infectious disease, shingles